The first patient was dosed in the Phase 1b/2a dose escalation trial of KINE-101.This study is conducted in Korea in patients with CIDP who have received at least one frontline treatment regimen. Kine Sciences advanced KINE-101 to the Phase 1b/2a study following the successful completion…